Emma Kleck has been totally dependent on insulin, the lifesaving medication for people living with diabetes, for 25 years.

As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

President Donald Trump just announced deals with drugmakers Eli Lilly and Novo Nordisk that will yield lower prices for GLP-1 ...

In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of ...

The World Health Organization issued new guidance this week on the use of popular GLP-1 drugs, like Ozempic, Wegovy, Mounjaro ...